NPHC · Nutra Pharma Corp
$0.00
+0.00 (+0.00%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Market Cap
$715,972
Shares
7.16B
Volume · Oct 19
928.01K
Avg daily vol (3M)
327.42K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.00
Avg vol 30d358K
Short int5K · 0.0% float · 1.0d
Short vol5%
DataJan 2020–Oct 2026
Filing10-Q · Aug 19
Up next
filed Aug 19, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$160,815
Trailing 12 months
Net income (TTM)
−$5.42M
Trailing 12 months
Revenue growth YoY
-59.2%
Year over year
Operating margin
-1,017.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$9.73M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-78.6%
Year over year · fewer shares
Price change (1Y)
+0.0%
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−50%
below
Price vs 50-day avg
0%
above
RSI (14)
40
neutral
MACD trend
Negative
52-week position
0%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
0%
trailing
YTD return
0%
this year
Relative strength
−8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -1.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
151%
contracting
Free cash flow
$-1.2M
Balance sheet
$9.7M
net debt
Quant / Vol
risk profile
Volatility
496%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
0.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−50%
Bearish
Price vs 50-day avg
0%
Neutral
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
Death cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -1.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -50%
vs 50-day avg +0%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| One third-party customer as % of net sales | 5% | the three months ended March 31, 2026 filing | — |
| Sales to Avini Health (related party) as % of total revenues | 43% | the three months ended March 31, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NPHC
this stock
Nutra Pharma Corp
|
$715,972 | +0.0% | +7.9% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$62.65B | +28.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.88B | +1.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$48.14B | +30.9% | +4.3% | 67.7 | 2.6% |
|
HLN
Haleon plc
|
$44.72B | +0.6% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NPHC | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +1.5% | +0.9% | -7.7% | -0.5% | -12.4% |